@article{APS5291,
author = {Hui-ling Li and Si-ming Xie and Liang Zhang and Cheng-jie Cai and Wei Wang and Jun Huang and Dao-yuan Wang and Dan-ping Wen and Qiu-hua Deng and Nan-shan Zhong and Jian-xing He},
title = {Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance to cisplatin, taxol, and gefitinib},
journal = {Acta Pharmacologica Sinica},
volume = {31},
number = {5},
year = {2016},
keywords = {},
abstract = {Aim: To Characterize a new human lung cancer cell line Am1010, derived from drug-surviving cells (DSCs).
Methods: The Am1010 cell line was established after 4 cycles of chemotherapy from an arm muscle metastasic tumor of a patient diagnosed with lung adenocarcinoma. The cell line has been remained in continuous culture for more than one year during this study.
Results: The Am1010 cell line demonstrated in vitro multi-drug-resistance to cisplatin, taxol, and gefitinib. The Am1010 cell doubling time without drug treatment was 42.395 h. The IC50 value of cisplatin was 4.299 μmol/L and >10 μmol/L for the Am1010 and P0318 (a cell line derived from non-DSCs) cells, respectively. The IC50 value of taxol was 0.067 μmol/L and >1 μmol/L for the Am1010 and P0318 cells, respectively. The IC50 value of gefitinib was 15.233 μmol/L and >70 μmol/L for Am1010 and P0318 cells, respectively. 11 genes involved in the focal adhesion and cell adhesion pathways were found to be differentially expressed. The cells of Am1010 have a significantly larger chromosome number than most lung cancer cell lines.
Conclusion: This novel DSCs derived lung cancer cell line will be a valuable in vitro tool for the investigation of lung cancer drug resistance and metastasis.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/5291}
}